Danaher Corporation (N:DHR)

Business Focus: Advanced Medical Equipment & Technology

Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology
See Regulatory Filings on SEC
Company Contact
Address: 2200 Pennsylvania Ave NW Ste 800w
WASHINGTON DC 20037-1731
Tel: N/A
Website: https://www.danaher.com
IR: See website
Key People
Steven M. Rales
Chairman of the Board
Daniel A. Raskas
Senior Vice President - Corporate Development
Matthew R. McGrew
Chief Financial Officer, Executive Vice President
Rainer M. Blair
Executive Vice President
Daniel L. Comas
Executive Vice President
Joakim Weidemanis
Executive Vice President
Robert S. Lutz
Senior Vice President, Chief Accounting Officer
Brian W. Ellis
Senior Vice President, Chief Compliance Officer, General Counsel
Angela S. Lalor
Senior Vice President - Human Resources
William H. King
Senior Vice President - Strategic Development
Business Overview
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through three segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification. Danaher's research and development, manufacturing, sales, distribution, service and administrative facilities were located in over 60 countries.
Financial Overview
For the six months ended 03 July 2020, Danaher Corporation revenues increased 11% to $9.64B. Net income applicable to common stockholders excluding extraordinary items increased 50% to $1.47B. Revenues reflect Life Sciences segment increase of 29% to $4.29B, Diagnostics segment increase of 4% to $3.29B. Net income benefited from Life Sciences segment income increase of 13% to $738M, Diagnostics segment income increase of 6% to $544.4M.
Employees: 60,000 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $166,843M as of Jul 3, 2020
Annual revenue (TTM): $17,515M as of Jul 3, 2020
EBITDA (TTM): $4,509M as of Jul 3, 2020
Net annual income (TTM): $2,796M as of Jul 3, 2020
Free cash flow (TTM): $3,178M as of Jul 3, 2020
Net Debt Last Fiscal Year: $16,848M as of Jul 3, 2020
Shares outstanding: 709,408,837 as of Jul 17, 2020
Index Membership: S&P 500
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.